Results 231 to 240 of about 315,787 (308)
Developmental and Epileptic Encephalopathy due to Biallelic Pathogenic Variants in PIGM
ABSTRACT Objective PIGM encodes a critical enzyme in the glycosylphosphatidylinositol (GPI)‐anchor biosynthesis pathway. While promoter‐region mutations in PIGM have been associated with a relatively mild phenotype characterized by portal vein thrombosis and absence seizures, recent evidence suggests that coding‐region mutations result in a more severe
Júlia Sala‐Coromina +11 more
wiley +1 more source
Performance analysis of various codec of voice traffic in IEEE 802.22 cognitive radio network module using NETSIM. [PDF]
Gowthaman S +3 more
europepmc +1 more source
ABSTRACT Objectives Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss.
Abdul Jaber Tayem +17 more
wiley +1 more source
Mainlobe Interference Suppression Based on POL-SPICE and Covariance Matrix Reconstruction for Polarization-Sensitive Arrays. [PDF]
Xiao B, He H, Wang L, Zhou T.
europepmc +1 more source
Sex Representation in US Stroke Clinical Trials: A Decade of Trends and Challenges
ABSTRACT Objective Stroke remains a major cause of disability and mortality in the US, with significant sex‐based disparities, and females remain underrepresented in stroke clinical trials. We aimed to examine sex representation in US‐based stroke clinical trials, identify trial characteristics associated with higher female enrollment (≥ 50%), and ...
Chaitali Dagli +5 more
wiley +1 more source
Performance of Space-Code-Division Multiple-Access Systems Using Reduced-Rank Detection
Jiliang Zhang +3 more
core +1 more source
Linear anti-jamming algorithm design for multi-channel optical fiber communication. [PDF]
Yu H.
europepmc +1 more source
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Whose voice counts? Public participation as a legal and commercial determinant of health in South Africa. [PDF]
Mahomedy S, Nzimande N.
europepmc +1 more source

